Qiagen N.v Stock News

An 8% increase in sales of its non-COVID products in Q4 2021 compared to the prior-year period helped Qiagen beat both on the top and bottom line.

Diagnostics company Qiagen on Tuesday projected 2022 profit above market estimates, signaling that a rebound in its non-COVID businesses would offset a drop in coronavirus testing demand.

Qiagen press release (QGEN): Q4 Non-GAAP EPS of $0.74 beats by $0.14.Revenue of $582M (+1.9% Y/Y) beats by $46.53M.QIAGEN initiates 2022 outlook for at least $2.07 billion net…

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Axsome To Pay $312,500 To Settle Patent Infringement Litigation With Baudax Axsome Therapeutics, Inc.

Qiagen (NYSE:QGEN) is scheduled to announce Q4 earnings results on Tuesday, February 8th, after market close.The consensus EPS Estimate is $0.60 (-11.8% Y/Y) and the consensus

QIAGEN (QGEN) said its QuantiFERON tuberculosis ((TB)) Gold Plus, the fourth generation of the test, received approval in China and a new endorsement from the World Health

QuantiFERON-TB Gold Plus (QFT-Plus), the fourth generation of the modern gold standard for TB detection, receives Chinese NMPA approval as test for active tuberculosis detection World Health Organization (WHO) endorses QFT-Plus as alternative IGRA test for diagnosis of TB infection, recommends new QIAreach QFT for research use in epidemiological settings QIAGEN N.V. (NYSE: QGEN , Frankfurt Prime Standard: QIA)) today announced that its QuantiFERON tuberculosis (TB) testing solution has gained additional momentum with the approval of the fourth generation of this modern gold standard test in China and a new endorsement from the World Health Organization (WHO). Among the recent developments: China''s National Medical Products Administration (NMPA) has approved QuantiFERON-TB Gold Plus (QFT-Plus) for TB diagnosis, including active TB infections. This builds on the regulatory approvals for QFT-Plus for latent TB diagnosis in the U.S. and other countries around the world, including CE-IVD marking.

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some bi

Growth-oriented investors may want to consider the following stocks, since they represent businesses with price-earnings ratios below 20 that recorded significant improvements in their trailing 12-mon

Investors continue to be optimistic about QIAGEN's (QGEN) progress with testing solutions and strategic collaborations.

Investors continue to be optimistic about QIAGEN's (QGEN) progress with testing solutions and strategic collaborations.

Qiagen (QGEN) ticked up 1.6% on report that bioMerieux is said to be still interested in a deal with the company. A deal may valued Qiagen (QGEN) at EURO 54 a share, according to

QIAGEN's (QGEN) artus SARS-CoV-2 Prep&Amp UM is faster than standard processes and can spot the virus more reliably, including the new Omicron variant.

We at Insider Monkey have gone over 867 13F filings that hedge funds and prominent investors are required to file by the SEC.

PUNE, India, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Global Next Generation Sequencing (NGS) Market is growing with a CAGR of 17.1% in the forecast period of 2022 to 2029 and is expected to reach USD 29,307.13 Million by 2029. The most appropriate, exclusive, realistic, and admirable Next Generation Sequencing (NGS) Market Research Report is delivered with devotion depending upon the business needs. With the precise base year and the historic year, estimations and calculations are performed in this industry report. Market share analysis and key trend analysis are the key accomplishing factors in this market report. Report helps to recognize how the market is going to perform in the forecast years by giving information about market definition, classifications, applications, and engagements. DBMR team provides Next Generation Sequencing (NGS) Market research report with loyalty that is promising and the way in which expected. Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-next-generation-sequencing-ngs-market Key Companies operating in the Next Generation Sequencing (NGS) Market are: Agilent Technologies Inc Thermo Fisher Scientific Inc QIAGEN Illumina Inc Bio-Rad Laboratories Inc Roche Sequencing (A subsidiary of F.